Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 5/20 | 0.58 |
| ▸ | DRD2 | P14416 | 2/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | MC4R | P32245 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12000243 | 0.84 | DRD4 (0.64) | DRD4DRD2DRD3SIGMAR1ALDH1A1 | |
| SCHEMBL14132945 | 0.81 | DRD4 (0.59) | DRD4DRD2DRD3SIGMAR1ALDH1A1 | |
| SCHEMBL29931970 | 0.80 | DRD4 (0.59) | DRD4DRD2DRD3SIGMAR1ALDH1A1 | |
| SCHEMBL7537231 | 0.80 | DRD4 (0.59) | DRD4DRD2DRD3SIGMAR1ALDH1A1 | |
| SCHEMBL2454168 | 0.80 | DRD4 (0.63) | DRD4DRD2DRD3SIGMAR1ALDH1A1 | |
| SCHEMBL23536367 | 0.80 | DRD4 (0.59) | DRD4DRD2DRD3SIGMAR1ALDH1A1 | |
| SCHEMBL2455105 | 0.80 | HTR3E (0.58) | DRD4MAPK1SIGMAR1ALDH1A1APOBEC3A | |
| SCHEMBL22635909 | 0.80 | NCF1 (0.58) | DRD4DRD2DRD3MAPK1KDM4E | |
| SCHEMBL415676 | 0.79 | DRD4 (0.55) | DRD4DRD2DRD3SIGMAR1ALDH1A1 | |
| SCHEMBL14094675 | 0.79 | DRD4 (0.55) | DRD4DRD2DRD3SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110262352-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2011-10-27 | — | — | US | disclosed |
| EP-2364303-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | Orion Corporation (FI) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010058060-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262352-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | ADRA2C, ADRA2A, HTR2C | DRD4 112/4885DRD2 16/4885DRD3 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.